This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, J. M.
Right arrow Articles by Horowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, J. M.
Right arrow Articles by Horowitz, S.
Related Collections
Right arrow Premature & Newborn

PEDIATRICS Vol. 100 No. 1 July 1997, pp. 24-30

Safety and Pharmacokinetics of Multiple Doses of Recombinant Human CuZn Superoxide Dismutase Administered Intratracheally to Premature Neonates With Respiratory Distress Syndrome

Received Sep 23, 1996; accepted Nov 18, 1996.

Jonathan M. Davis*, Warren N. Rosenfeld*, Susan E. Richter*, Richard ParadDagger , Ira H. Gewolb§, Alan R. Spitzerparallel , Waldemar A. Carlo, Robert J. Couser#, Anita Price**, Edith FlasterDagger Dagger , Nadim Kassem§§, Lionel Edwards§§, Joan Tierney||, and Stuart Horowitz||

From the * Departments of Pediatrics (Neonatology), ** Radiology, Dagger Dagger  Biostatistics, and || CardioPulmonary Research Institute, Winthrop-University Hospital, SUNY Stony Brook School of Medicine, Mineola, NY; Dagger  Brigham and Women's Hospital, Harvard Medical School, Boston, MA; § University of Maryland Medical Center, Baltimore MD; parallel  Thomas Jefferson University Medical Center, Philadelphia, PA;  University of Alabama at Birmingham, Birmingham, AL; # Children's Healthcare-Minneapolis, Minneapolis, MN; and §§ Bio-Technology General Corp, Iselin, NJ; for the North American rhSOD Study Group.

Objectives.  To examine the safety and pharmacokinetics of multiple intratracheal (IT) doses of recombinant human CuZn superoxide dismutase (rhSOD) in premature infants with respiratory distress syndrome who are at risk for developing bronchopulmonary dysplasia (BPD).

Methods.  Thirty-three infants (700 to 1300 g) were randomized and blindly received saline, 2.5 mg/kg or 5 mg/kg rhSOD IT within 2 hours of surfactant administration. Infants were treated every 48 hours (as long as endotracheal intubation was required) up to 7 doses. Serial blood and urine studies, chest radiographs, neurosonograms, SOD concentration and activity measurements, and tracheal aspirate (TA) inflammatory markers were assessed throughout the 28-day study.

Results.  SOD concentrations in serum (0.1 [0.05/0.15] µg/mL-geometric mean with lower/upper confidence intervals), tracheal aspirates (TA) (0.2 [0.1/0.3] µg/mL) and urine (0.3 [0.2/0.4] µg/mL) were similar at baseline in all 3 groups and did not change significantly in the placebo group. In the rhSOD treatment groups, SOD concentrations were increased on day 3 and did not change significantly thereafter over the 14-day dosing period (also measured on days 5, 7, and 13). SOD concentrations averaged 0.4 [0.3/0.5] µg/mL in serum, 0.8 [0.6/1.2] µg/mL in TA and 1.1 [1.0/1.3] µg/mL in urine for the low-dose group and 0.6 [0.5/0.7] µg/mL in serum, 1.1 [0.9/1.5] µg/mL in TA, and 2.2 [1.6/2.9] µg/mL in urine for the high-dose group over the 14-day dosing period. Enzyme activity directly correlated with SOD concentration and rhSOD was active even when excreted in urine. TA markers of acute lung injury (neutrophil chemotactic activity, albumin concentration) were lower in the rhSOD agroups compared with placebo. No significant differences in any clinical outcome variable were noted between groups.

Conclusions.  These data indicate that multiple IT doses of rhSOD increase the concentration and activity of the enzyme in serum, TA and urine, reduce TA lung injury markers and are well-tolerated. Further clinical trials examining the efficacy of rhSOD in the prevention of BPD are warranted.

Key words: antioxidants, superoxide dismutase, bronchopulmonary dysplasia, respiratory distress syndrome.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Lakshminrusimha, J. A. Russell, S. Wedgwood, S. F. Gugino, J. A. Kazzaz, J. M. Davis, and R. H. Steinhorn
Superoxide Dismutase Improves Oxygenation and Reduces Oxidation in Neonatal Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., December 15, 2006; 174(12): 1370 - 1377.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H.-c. Koo, J. M. Davis, Y. Li, D. Hatzis, H. Opsimos, S. Pollack, M. S. Strayer, P. L. Ballard, and J. A. Kazzaz
Effects of transgene expression of superoxide dismutase and glutathione peroxidase on pulmonary epithelial cell growth in hyperoxia
Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L718 - L726.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. Arita, A. Joseph, H.-C. Koo, Y. Li, T. A. Palaia, J. M. Davis, and J. A. Kazzaz
Superoxide dismutase moderates basal and induced bacterial adherence and interleukin-8 expression in airway epithelial cells
Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1199 - L1206.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. B. Mamo, H. B. Suliman, B.-L. Giles, R. L. Auten, C. A. Piantadosi, and E. Nozik-Grayck
Discordant Extracellular Superoxide Dismutase Expression and Activity in Neonatal Hyperoxic Lung
Am. J. Respir. Crit. Care Med., August 1, 2004; 170(3): 313 - 318.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. M. Davis, R. B. Parad, T. Michele, E. Allred, A. Price, and W. Rosenfeld
Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase
Pediatrics, March 1, 2003; 111(3): 469 - 476.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. N. Ahmed, H. B. Suliman, R. J. Folz, E. Nozik-Grayck, M. L. Golson, S. N. Mason, and R. L. Auten
Extracellular Superoxide Dismutase Protects Lung Development in Hyperoxia-exposed Newborn Mice
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 400 - 405.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. H. STEINHORN, G. ALBERT, D. D. SWARTZ, J. A. RUSSELL, C. R. LEVINE, and J. M. DAVIS
Recombinant Human Superoxide Dismutase Enhances the Effect of Inhaled Nitric Oxide in Persistent Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 834 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. M. Ilizarov, H.-C. Koo, J. A. Kazzaz, L. L. Mantell, Y. Li, R. Bhapat, S. Pollack, S. Horowitz, and J. M. Davis
Overexpression of Manganese Superoxide Dismutase Protects Lung Epithelial Cells against Oxidant Injury
Am. J. Respir. Cell Mol. Biol., April 1, 2001; 24(4): 436 - 441.
[Abstract] [Full Text]